Table 1

Correlations between LFA-REAL ClinRO and SLE disease activity measures, LFA-REAL PRO and other PRO measures, PGA with SLEDAI and BILAG at baseline, 24 and 52 weeks

BaselineWeek 24Week 52BaselineWeek 24Week 52BaselineWeek 24Week 52
BILAG0.430.670.73Lupus QoL−0.42−0.47−0.46SLEDAI-2K0.090.450.52
SLEDAI-2K0.350.600.62SF-36v2 vitality−0.40−0.43−0.58
SF-36 PCS−0.45−0.53−0.53
  • Correlation scale: very weak: 0–0.2; weak: 0.2–0.4; moderate: 0.4–0.6; strong: 0.6–0.8; very strong: 0.8–1.0. P<0.001 across all correlation analyses.

  • (A) Correlations between LFA-REAL ClinRO Total Score and SLE disease activity measures. LFA-REAL ClinRO; LFA-REAL PRO; SLEDAI-2K; BILAG; PGA.

  • (B) Correlations between LFA-REAL PRO Total Score and PRO measures. LFA-REAL PRO; SF-36; SF-36 PCS; Lupus QoL; FACIT-F. The LFA-REAL PRO increases with disease severity while the other PROs increase with improvement, accounting for the inverse correlations observed.

  • (C) Correlations between PGA and SLEDAI and BILAG.

  • BILAG, British Isles Lupus Assessment Group 2004 Index Total Score; ClinRO, clinician-reported outcome; FACIT-F, Functional Assessment of Chronic Illness Therapy Fatigue Scale; LFA-REAL, Lupus Foundation of America Rapid Evaluation of Activity in Lupus; Lupus QoL, Lupus Quality of Life questionnaire; PGA, Physician Global Assessment; PRO, patient-reported outcome; SF-36, 36-item Short-Form Health Survey; SF-36 PCS, 36-item SF-36 Physical Component Summary; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.